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Systematic review estimating the burden of 
dementia in the WHO Southeast Asia Region 
using Bayesian and frequentist approaches
Background Rapid increase in life expectancy in low- and middle-income 
countries including the World Health Organization’s Southeast Asia Region 
(SEAR) has resulted in an increase in the global burden of dementia, which is 
expected to become a leading cause of morbidity. Accurate burden estimates 
are key for informing policy and planning. Given the paucity of data, estimates 
were developed using both a Bayesian methodology and as well as a tradition-
al frequentist approach to gain better insights into methodological approaches 
for disease burden estimates.
Methods Seven databases were searched for studies published between 2010-
2018 regarding dementia prevalence in SEAR, generating 8 relevant articles. A 
random-effects model (REM) and a Bayesian normal-normal hierarchical mod-
el (NNHM) were used to obtain the pooled prevalence estimate of dementia 
for people aged 60 and above in SEAR. The latter model was also developed 
to estimate age-specific dementia prevalence. Using UN population estimates 
for SEAR, total and age-specific projections of the burden of dementia in 2015, 
2020 and 2030 were calculated.
Results The prevalence of dementia in SEAR was found to be 3% (95% con-
fidence interval (CI) = 2-6%) in those above age 60 based on REM, and 3.1% 
(95% credible interval = 1.5-5.0%) based on the NNHM. The estimated preva-
lence varies with age, increasing from 1.6% (95% credible interval = 0.8-2.5%) 
in people aged 60-69 to 12.4% (95% credible interval = 5.6-20%) in people 
above the age of 80. The risk of developing dementia increased exponential-
ly with age. The number of people living with dementia in SEAR in 2015 was 
estimated at 5.51 million (95% credible interval = 2.66-8.82 million, with pro-
jections of 6.66 million (95% credible interval = 3.21-10.7), in 2020 and 9.6 
million (95% credible interval = 4.62-15.36) in 2030.
Conclusion The burden of dementia in SEAR is substantial and will continue to 
increase reapidly by 2030. The lack of research focusing on dementia in SEAR 
points to a significant under-recognition of this disease. The projected rise in 
dementia cases in the future should prompt urgent governmental response to 
address this growing public health issue. We also argue that given the overall 
paucity of data for the region, the Bayesian approach offers a promising meth-
odology for improved estimates of disease prevalence and burden and should 
continue to be explored.
Electronic supplementary material: 
The online version of this article contains supplementary material.
© 2020 The Author(s)
JoGH © 2020 ISGH
In 2015, an estimated 47 million people worldwide suffered from dementia, a 
major incapacitating syndrome defined by the progressive loss of cognitive ability 
and independent living beyond normal aging [1]. This figure is predicted to rise to 
75 million by 2030, and 132 million by 2050, and has a bigger economic impact 
than cancer, heart disease and stroke combined [2]. In 2015, an estimated US$818 
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billion was spent on dementia (1.1% of global Gross Domestic Product), and that is expected to rise to 
US$2 trillion by 2030 [1]. Due to their large, rapidly aging populations, low- and lower-middle-income 
countries (LMICs) are expected to bear an increasing majority of this burden, accounting for up to 71% 
of global dementia cases by 2050 [1]. The condition not only negatively affects the quality of life of peo-
ple living with dementia (PWD), but also imposes significant financial, emotional and opportunity costs 
on their families and caregivers, and it strains social and health resources. Despite medical advancements 
and breakthroughs taking place in this century, there is currently no cure or disease-modifying treatment.
The World Health Organization’s (WHO) Southeast Asia Region (SEAR), consisting mainly of LMICs, is the 
second most populated region of the world, with a quarter of its population (1.9 billion) [3]. There have only 
been three prior estimates that include dementia in the SEAR region, with the more recent covering estimates 
for the period of 1980-2009 [4-6]. Rapid economic, health and demographic transitions have occurred in 
this region since the last estimates were published, leading to a rise of non-communicable diseases includ-
ing dementia. The evidence for dementia in the SEAR region has also been expanded over the last decade. 
Therefore, a separate and more comprehensive study of SEAR with updated estimates is urgently needed.
While disease burden estimates have traditionally relied on the frequentist analytic approach [7-9], Bayes-
ian methods are growing in popularity in medical research (e.g., Prince 2013 [5]; Nichols 2019 [6]. The lat-
ter framework is considered more appropriate for meta-analyses with very few available studies because it 
allows additional information to be incorporated into current estimates [7,8]. That additional information, 
embedded in a prior, introduces a natural form of regularisation into the estimation procedure, helping to 
improve precision. Other, similar meta-analyses are ideal sources for that information: they represent cred-
ible distillations of available scientific evidence. With existing meta-analytic evidence forming the basis for 
the prior, the posterior produced by the Bayesian procedure can be interpreted as an updated summary. This 
in turn ensures consistency between current and prior estimates [9]. Two global health organizations that 
work on the global prevalence of dementia have both opted for Bayesian methods. The estimates produced 
by Prince and colleagues in 2013 assumed that the prevalence of dementia follows a gamma distribution 
[5]. The latest regional dementia estimate published in 2019 by the Institute for Health Metrics and Evalua-
tion (IHME) used a Bayesian method [6]. An optimal approach, however, has not yet been determined and 
methods for Bayesian application to prevalence estimates is an area of ongoing study.
The overall aim of this study is to update the dementia prevalence estimates for SEAR with greater ac-
curacy through utilizing two approaches to estimation: frequentist and Bayesian. We aim to achieve 
this by conducting a comprehensive systematic review of data that has emerged from the region since 
2009, when the previous estimates were published, using a greater number of academic databases. 
Given the paucity of data, we decided to use the Bayesian approach with confirmation by the tradi-
tional frequentist approach to generate more reliable estimates for disease burden. Generating appro-
priate models for Bayesian analysis may be challenging and thus we explored the use of the Bayesian 
Random-Effects Meta-Analysis (bayesmeta), a newer and simpler to operate statistical open source 
package in R. It is hoped that the updated estimates will help draw attention to the growing burden of 
dementia in SEAR as part of a global trend. This study can inform policy and planning, while meth-
odological insights generated from the comparison of analytic approaches will guide development of 
future disease burden estimates.
METHODS
Study selection
We sought to include prospective population-based studies of dementia prevalence in countries in the 
WHO’s SEAR published between 2010 and November 2018. The study was conducted and reported in 
accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guide-
lines [10] and involved a parallel systematic review conducted in May and November 2018 of studies 
on the epidemiology of dementia. Seven databases were searched: PubMed, MEDLINE, EMBASE, Glob-
al Health Library (CABI), Global Index Medicus, PsycInfo, and the BIOSIS Citation Index (Table S1 and 
Appendix S1 in the Online Supplementary Document).
1,556 studies were identified with 2 additional studies found through hand searches of reference lists. 
After the removal of duplicates, 1,216 articles remained of which 1,160 articles were further excluded 
based on the title relevance. 56 abstracts were then screened and 19 full–text articles were then analysed 
for inclusion/exclusion criteria, study design and the use of case definitions. The remaining 8 studies were 
Burden of dementia in the WHO Southeast Asia Region
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used for a meta-analysis [11-18]. See Figure 1 for the PRIS-
MA diagram on study selection.
The included papers were critically appraised using the 
modified Joanna Briggs Institute (JBI) Critical Appraisal 
checklist for prevalence studies [5,19] (Table S2; Appendix 
S2 in the Online Supplementary Document). For each el-
igible study, we extracted the following data: country where 
the study was conducted, urban/rural setting, the period 
of study, sample size (denominator), number of dementia 
cases (numerator) and/or unweighted dementia prevalence. 
Wherever possible, data by age group, gender and types of 
dementia were also extracted.
Study characteristics
The 8 included studies took place in 2 countries of the 
SEAR – 7 from India [11-13,15-18] and 1 from Thailand 
[15]. Half of the studies were conducted in urban settings 
[11,16-18] while the other half were carried out in rural 
areas [12-15]. All studies took place between 2010 and 
2017. Most studies adopted a two-stage design, which in-
volved an initial screening by field workers and confirma-
tion of dementia cases by a specialist. 2 out of 8 studies 
also included a third stage where researchers screen neg-
ative cases to identify false positives [11,15]. Most studies 
used a modified version of the Mini-Mental Status Exam 
(MMSE) as a screening tool. DSM-IV and ICD-10 were the 
most popular diagnostic tools used for case ascertainment. 
The study details can be found in Table 1.
Table 1. Study details
Study AuthorS (yeAr) region/Country Setting SCreening toolS outCome ASCertAinment Study deSign
1 Banerjee (2017) [11] Kolkata, India Urban KBSB DSM-IV; 
NINCDS-ADRDA; 
NINCDS-AIREN
3-stage design  
cross-sectional study*
2 Gurukartick (2016) [12] Thiruvennainallur in  
Villupuram District of Tamil 
Nadu, India
Rural VSID DSM-IV 2-stage design  
cross-sectional study†
3 Gambhir (2014) [13] Chiraigaon block of Varanasi 
District, India
Rural HMSE DSM-IV-TR;  
ICD-10
2-stage design  
cross-sectional study†
4 Senanarong (2013) [14] Siriraj, Thailand Rural TMSE DSM-IV 2-stage design  
cross-sectional study†
5 Tiwari (2013) [15] Luchnow, India Rural HMSE;  
CAMDEX-R
DSM-IV; ICD-10 3-stage design  
cross-sectional study*
6 Seby (2011) [16] Pune district of Maharashtra 
State, India
Urban GHQ-12; 
MMSE
ICD-10 2-stage design  
cross-sectional study†
7 Mathuranath (2010) [17] Trivandrum, Kerala State, 
India
Urban ACE; MMSE DSM-IV; NINCDS-
ADRDA; Hachins-
ki’s Ischemic Scale
2-stage design  
cross-sectional study†
8 Saldanha (2010) [18] Pune and Kirkee canton-
ments, Maharashtra, India
Urban MMSE; CSI-D ICD-10 Single phase  
cross-sectional survey
KCSB – Kolkata Cognitive Screening Battery, VSID – Vellore Screening Instrument for Dementia , HMSE – Hindi Mini Mental state examination, TMSE – 
Thai Mental State Examination, CAMDEX-R – Cambridge Examination for Mental Disorders of the Elderly – Revised (CAMDEX-R), GHQ-12 – General 
Health Questionnaire-12, MMSE – Mini Mental State Examination, ACE – Addenbrooke’s Cognition Examination, CSI-D – 10/66 Research Group Com-
munity Screening Instrument for Dementia, ICD – International Classification of Diseases, DSM – Diagnostic and Statistical Manual of Mental Disorders, 
NINDS-AIREN – National Institute of Neurological Disorders and Stroke Association criteria for vascular dementia, NINCDS-ADRDA – National Institute 
of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association criteria for Alzheimer’s disease
*3-stage design cross-sectional study: 1. Screening by trained fieldworkers; 2. Confirmation of suspected cases by consultant psychiatrists/ psychiatric 
team; 3. Checking of unsuspected cases by consult psychiatrists/ psychiatric team for false negatives.
†2-stage design cross-sectional study: 1. Screening by trained fieldworkers; 2. Confirmation of suspected cases by consultant psychiatrists/ psychiat-
ric team.
Figure 1. PRISMA flow diagram for selection of studies included 
in the systematic review.
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The total sample size for the 8 studies combined was 28 543 participants. There was considerable vari-
ation in the number of participants between studies, ranging from 202 to 17 584 (Table 2). The medi-
an study sample size was 2072. All studies included individuals aged 50 years and above, and the most 
common classifications of age groups were age 60 years and above or age 65 years and above. Two stud-
ies recruited a regionally representative sample by taking into account the cultural and socioeconomic 
background of the participants [11-17]. The remaining studies used representative samples of the rural 
or urban community dwelling elderly populations. The proportion of female participants was around the 
same as male participants.
Table 2. Detailed sampling characteristics
Study AuthorS (yeAr) SAmple SeleCtion pArtiCipAnt reCruitment SAmple Size And reSponSe rAte pArtiCipAntS trAitS
1 Banerjee (2017) [11] Representative of the re-
gion in terms of socioeco-
nomic and cultural levels
Stratified and ran-
dom sampling
100 802 approached and 
analysed
47.2% female, ≥50 
years old
Attrition <1%
2 Gurukartick (2016) [12] Rural community dwelling 
elderly population
Random and pro-
portional sampling
1304 analysed 44.9% female, ≥65 
years oldSample size calculation 
≥1300
3 Gambhir (2014) [13] Rural community dwelling 
elderly population
Random sampling 728 analysed 64.4% female, ≥60 
years old54-80% for female
4 Senanorong (2013) [14] Rural community dwelling 
elderly population
Catchment from 
primary care unit of 
Siriraj Hospital
1998 approached, 1973 
analysed (98.7%)
65.1% female, ≥60 
years old
Sample size calculation 
≥1948
5 Tiwari (2013) [15] Rural community dwelling 
elderly population
Random sampling 2324 approached, 2146 
analysed (92.3%)
52.6% female, ≥60 
years old
Sample size calculation 
≥ 2060
6 Seby (2011) [16] Urban community dwell-
ing elderly population
Consecutive sam-
pling
218 approached, 202 
analysed (92.7%)
49.1% female, ≥65 
years old
7 Mathuranath (2010) [17] Representative of the re-
gion in terms of socioeco-
nomic and cultural levels
Door to door sur-
vey
2690 eligible, 2446 ana-
lysed (90.9%)
59.4% female, ≥55 
years old
8 Saldanha (2010) [18] Community dwelling pop-
ulation
Random sampling 
then door to door 
survey
2145 approached, 2119 
analysed, (98.8%)
60.5% female, ≥65 
years old
Quality assessment
There was considerable variation in the quality of the included studies (Appendix S2 in the Online Sup-
plementary Document). The quality score ranged from 12 to 17 out of 18. Out of 8 studies, 2 study 
samples were representative of the target population [11,17] and 3 were sampled in an unbiased manner 
[11,14,17]. In general, sample sizes were appropriate, and 3 studies carried out a sample size calcula-
tion prior to recruitment [12,14,15]. Most studies clearly documented exclusion criteria, the number of 
refusals and loss to follow-up. Response rates were high overall: 6 had a response rate over 90% [11,14-
18]. All studies used a well-recognized diagnostic manual and conducted different tests to exclude other 
conditions with similar clinical manifestations. For instance, all studies made effort to exclude depression 
as a differential diagnosis.
Data analysis
Given the paucity of data, dementia prevalence was estimated using a Bayesian approach and confirmed by 
a frequentist approach. This allows for comparison of the validity of estimates particularly given the lim-
itations in data availability and the opportunity to explore the utility of using a simpler statistical package 
to generate a normal-normal hierarchical model (NNHM) for disease burden estimates with limited data. 
All analyses were conducted using the statistical software R (version 3.5.2, R Core Team, Vienna, Austria).
Bayesian approach
A Bayesian approach allows for estimates based on smaller numbers of studies by allowing prior estimates 
to be incorporated, which improves precision [7-9]. For instance, the 2009 estimate of 6.38% demen-
Burden of dementia in the WHO Southeast Asia Region
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tia prevalence in SEAR for people age ≥60 [4] indicates that the 2020 prevalence will probably be under 
10%. If an updated meta-analysis included studies that were methodologically flawed or were based on 
a highly biased sample that produced an unrealistic prevalence (eg, >25%), the outlier effect would be 
restrained due to prior knowledge [9].
The interpretation of results generated by a Bayesian approach is also more intuitive. In the frequentist 
analysis, the concept of confidence interval is commonly misunderstood [20]. A 95% confidence interval 
(CI) means that if we were to take repeated samples from the population, and calculate the confidence 
intervals each time, then it would be expected that 95% of the calculated confidence intervals would be 
such as to include the true population parameter [21]. 95% credible interval produced from the Bayesian 
analysis, on the other hand, means that given the observed data, there is a 95% probability that the true 
value of prevalence falls within the credible interval [20]. This means that the credible intervals produced 
are much more relevant in global health research.
The age-specific prevalence was pooled using the bayesmeta package of R [20]. The Bayesian method 
can allow us to update the current state of knowledge by considering the newly extracted data along-
side previously published literature. In 2009, Alzheimer’s Disease International (ADI) published the 
age-specific prevalence of dementia for different world regions [4]. The age-specific prevalence of de-
mentia in South Asia published by ADI was used to inform the specification of the prior for the Bayes-
ian approach. Importantly, the ADI’s analysis was based on studies that are entirely distinct from those 
included in this work. Only studies with age-specific prevalence data were included in the meta-anal-
ysis. A Bayesian normal-normal hierarchical model (NNHM) was constructed with age groups as the 
independent variable and age-specific prevalence as the dependent variable. The NNHM model was 
chosen because it mirrors many of the key distributional assumptions embedded within the frequen-
tist random-effects model [20,22].
The number of participants screened and the number of PWD identified from each study were first sorted 
into 10-year age group bins. Participants over the age of 80 were all allocated into an “over 80” bin. Pre-
vious research has held that dementia is rare among younger individuals and the prevalence of the dis-
ease increases with age. However, the evidence on the rate itself is mixed, particularly for older cohorts. 
To reflect this pattern of uncertainty, we set the prior variance to increase with age: for age groups 60-69, 
70-79 and over 80, it was 0.092, 0.152 and 0.32 respectively. The prevalence estimates for each of these 
groups were pooled, and 95% credible intervals were obtained.
As a sensitivity test for the baysmeta package, Just another Gibbs sampler (JAGS) was used to construct a 
more traditional model simulated via Markov chain Monte Carlo (MCMC) methods, which produced es-
timates of disease burden for each age group bin highlighted above using a similar NNHM model. JAGS 
is an open source algorithm used often in Bayesian analysis to simulate draws from target posterior dis-
tributions [23].
Frequentist approach
Crude prevalence estimates were pooled using a frequentist approach with the metafor package of R [24]. 
Given the available evidence, which strongly indicates a degree of heterogeneity in prevalence rates with-
in the region, a random effects model was thought most appropriate. Note the subtle point that we are 
interested in conducting inference about the SEAR dementia prevalence rate in general – that is, uncon-
ditional inference in the language of [25]. Again, this suggests the REM is the most suitable frequentist 
model to adopt. All studies with crude prevalence estimates were included in the analysis.
To assess heterogeneity between studies, Cochrane’s Q test, I-squared (I2) statistics and tau-squared (т2) 
statistics were examined. Cochrane’s Q test tests the null hypothesis that the true prevalence is the same 
in all primary studies included in the meta-analysis. A p-value of less than 0.05 shows evidence to reject 
the null hypothesis and indicates the presence of statistical heterogeneity among the included studies [26]. 
The I2 statistic represents the percentage of total variation across studies that is due to true heterogeneity 
instead of chance. Generally, I2 values of 25%, 50% and 75% are interpreted as low, moderate and high 
heterogeneity [27]. т2 is the variance of the prevalence parameter across the population of studies and re-
flects, again, heterogeneity in the true prevalence rate [28].
Burden estimation
The number of PWD in 2015, 2020 and 2030 was estimated by multiplying the prevalence obtained by 
both methods with the number of people from SEAR in 2015, 2020 and 2030 using data from the UN 
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Population Division [29]. The burden of dementia in each age group was only estimated with the Bayes-
ian model and is calculated by multiplying the age-specific prevalence and the number of people in the 
corresponding age groups in 2015, 2020 and 2030. Note these projections are made on a ceteris paribus 
basis: they allow only for changes to the population size; the prevalence rate and other key parameters 
are assumed to be constant through time.
RESULTS
Prevalence estimates
Five studies reported age-specific prevalence of dementia [12,14,17-19] and were included in the Bayes-
ian NNHM. For people aged 60 and above, dementia prevalence was found to be 3.1% (95% credible 
interval = 1.5-5.0%). The prevalence of dementia ranged from 1.6% (95% credible interval = 0.8-2.5%) in 
those between 60-69 years of age to 12.4% (95% credible interval = 5.6-20%) in those above the age of 80 
(Table 3). As a test of the sensitivity of the results, we conducted the analysis using a modified NNHM 
prior setup and estimated the model via classical MCMC methods: with that, we obtained similar results 
(Appendix S3 in the Online Supplementary Document).
All 8 studies reported overall dementia prevalence and were pooled using REM (Figure 2). Based on the 
frequentist model, the unadjusted crude prevalence for people over 60 years was estimated to be 3.0% 
(95% CI = 2-6%). Cochrane’s Q test revealed that there was significant heterogeneity among the included 
studies. True heterogeneity, indicated by I2, was above 90%, which was very high. The variance of prev-
alence parameter across the study populations, or т2, was 0.82.
Burden estimates
Overall, there were 175.7 million people aged 60 and above in SEAR in 2015. This number is projected 
to increase to 209.2 million in 2020 and 292.7 million in 2030 [29]. Based on the results obtained with 
the Bayesian NNHM model, we estimate that the number of PWD will increase from 5.51 million (95% 
credible interval = 2.66-8.82 million) in 2015 to 6.66 million (95% credible interval = 3.21-10.7 million) 
in 2020. In 2030, it is projected that there will be nearly 10 million (9.60 million, 95% credible inter-
val = 4.62-15.36 million) PWD in SEAR (Figure 3, Table 4). Similarly, based on the REM, we estimate 
there were 5.21 million (95% CI = 3.47 - 10.40 million) PWD in SEAR in 2015 (Table 4). The number 
Figure 2. Crude prevalence for individuals over age 60.
Table 3. Prevalence of dementia in 10-year age groups in SEAR
Age pooled prevAlenCe eStimAte (95% 
Credible intervAl)
number of pWd in SeAr in 2015 
(thouSAndS)
projeCted number of pWd in SeAr in 
2020 (thouSAndS)
projeCted number of pWd in SeAr in 
2030 (thouSAndS)
60-69 0.016 (0.008-0.025) 1691.90 (845.95-2,643.60) 2063.18 (1031.59-3223.73) 2733.55 (1366.78-4271.18)
70-79 0.034 (0.017-0.055) 1739.41 (869.70-2,813.75) 2,021.50 (1010.75-3270.08) 3115.76 (1557.88-5040.20)
≥80 0.124 (0.056-0.200) 2082.46 (940.46-3,358.80) 2579.70 (1165.02-4160.80) 3747.65 (1692.49-6044.60)
≥60 0.0314 (0.015-0.050) 5513.77 (2656.12-8816.15) 6664.38 (3207.37-10 654.61) 9596.96 (4,617.14-15 355.98)
PWD – people with dementia, SEAR – Southeast Asia Region
Burden of dementia in the WHO Southeast Asia Region
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of PWD is projected to increase to 6.28 million (95% CI = 4.18-
12.6 million) in 2020 and 8.78 million (95% CI = 5.85-17.60 
million) in 2030.
The Bayesian NNHM model was also used to estimate the bur-
den of dementia in each 10-year age group (Table 3). People 
over the age of 80 had the highest estimated burden of dementia, 
with 2.08 million (95% credible interval = 0.94-3.36 million) in 
2015. This burden is projected to rapidly increase to 2.58 mil-
lion (95% credible interval = 1.17-4.16 million) in 2020 and 3.75 million (95% credible interval = 1.69-
6.04 million) in 2030.
DISCUSSION
We aimed to estimate the prevalence of dementia in the WHO’s SEAR and adopted both Bayesian and 
traditional frequentist approaches to optimize our understanding of the burden of dementia within this 
region. We searched for studies published in the English language between 2010 and 2018 and ultimate-
ly found 8 for inclusion, 7 of which were from India, and 1 was conducted in Thailand. The Bayesian 
approach may be more useful in regions with limited data availability. We therefore compared it to the 
traditional frequentist approach, which is more commonly used in studies with larger amounts of data 
available. Our Bayesian estimates revealed that there were about 5.51 million people living with dementia 
in SEAR in 2015, consistent with the most recent estimates produced by IHME, which found that there 
were 5.47 million people with dementia in SEAR in 2016 [6].
Despite our best efforts to estimate dementia prevalence in Southeast Asia, current epidemiological knowl-
edge of dementia prevalence in this region proved to be sparse. Out of the eleven countries in the area, 
only India and Thailand provided studies with sufficient data. Indonesia and Bangladesh are the third 
most populated countries in Southeast Asia after India, which may be most affected by dementia in the 
upcoming years, yet lack of published studies makes it extremely difficult to assess and predict the impact 
dementia will have on these countries. With an estimated 5.51 million already living with dementia and 
close to 10 million projected to be affected by 2030, urgent public health action is necessary.
The crude prevalence of dementia in people aged 60 years and above was 3.0% (95% CI = 2-6%) based 
on all included studies. The age-adjusted prevalence of dementia was 3.1% (95% credible interval = 1.5-
5.0%). As the majority of the included studies in this current review came from India, the most com-
parable (external) prevalence estimate was an estimate produced by the Alzheimer’s and Related Disor-
ders Society of India in 2010. They found that the prevalence of dementia in India ranged from 0.6% 
to 3.5% in rural areas and 0.9% to 4.8% in urban areas [30]. Our estimate, therefore, is consistent with 
the findings of current literature. This review also supports the long established relationship between age 
and prevalence of dementia. The prevalence ranged from 1.6% in the 60-69 age group to 12.4% in the 
above 80 age group. In comparison, sensitivity analysis using Bayesian approach with the JAGS sampler 
Table 4. Burden estimate comparisons between Bayesian 
and frequentist models
yeAr bAyeSiAn nnhm rAndom-effeCtS model
2015 5.51 (2.66-8.82) million* 5.21 (3.47 - 10.40) million
2020 6.66 (3.21-10.7) million 6.28 (4.18 – 12.60) million
2030 9.60 (4.62-15.36) million 8.78 (5.85 –17.56) million
NNHM – normal-normal hierarchical model
Figure 3. Projected dementia cases in SEAR by Bayesian and frequentist models. Note: Due to the conceptual differ-
ences between the analytic approaches we would like to remind the reader that the 95% confidence intervals (Ran-
dom-effects model) and 95% credible intervals (Bayesian) cannot be interpreted interchangeably.
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showed similar though slightly higher prevalence estimates with 2.3% for ages 60-69, 4.9% for ages 70-
79, 13.5% for above age 80, respectively.
The Delphi Consensus reported prevalence of dementia for two regions in Southeast Asia – SEAR B which 
includes Indonesia, Thailand and Sri Lanka, and SEAR D which is comprised of India and South Asian 
countries. Their estimates for SEAR D which include India and are most comparable to this research show 
that the prevalence of dementia varied between 0.4% in those between 60-64 to 14% in people above 85. 
However, it is more difficult to make comparisons of current estimates to the SEAR B region, as this review 
did not include any study from those regions in the data analysis. A more recent meta-analysis conduct-
ed by Prince et al in 2013 included five studies that showed how dementia prevalence in the South Asia 
region (most comparable to this review as it included India) for individuals over age 60 was 5.8% [5].
Given that an optimal approach to estimating disease burden continues to be an area of research, the results 
lend validity to the use of the Bayesian NNHM approach as adopted in this review and support its further 
use. Future research is needed to explore the role of varying statistical approaches in prevalence and bur-
den of disease estimates, but the results of this paper are promising, particularly in settings with limited 
data availability as in this review. Furthermore, the ability to use a user-friendly open source software to 
run complex full Bayesian analysis like bayesmeta allows for easier incorporation of this approach in fu-
ture studies and allows greater accessibility to estimate burden of disease for researchers across the globe.
The use of PRISMA guidelines, careful selection of studies, and the use of validated quality assessment 
tools to ensure research rigour were strengths of this review. However, despite efforts to provide the best 
possible estimate of the prevalence of dementia in SEAR, there were some limitations. First, while the 
studies were carefully selected and chosen based on the quality of conducted research, the sample size of 
each study was relatively small compared to the overall population of the respective countries. Second, 
the estimates of the current study were based on only 2 of the 11 countries in the SEAR (mainly India, 
and to a lesser extent Thailand). The paucity of data from the rest of the region represents a serious lim-
itation of our work. Third, the other countries in this region all have very distinct cultures and levels of 
development, which would plausibly lead to variation in their citizens’ level of dementia risk. Fourth, the 
articles were restricted to English language only, potentially limiting the research from countries which 
may not have a large number of English publications. Fifth, some studies only included participants that 
speak Hindi, Thai or English, possibly underestimating the true number of participants suffering from de-
mentia as many may be excluded for not speaking these languages. Sixth, sex-and age-specific prevalence 
of dementia could not be estimated due to lack of reporting from the included studies. Seventh, very few 
studies reported information on specific dementia types, making it difficult to estimate the prevalence of 
dementia subtypes (eg, Alzheimer’s disease, vascular dementia). Lastly, it is worth underscoring that our 
estimates of the burden of dementia crucially relied on a number of strong assumptions: the prevalence 
remains the same and the population structure progresses as predicted by the UN estimates. It is likely 
that these will not be borne out. Nevertheless, the estimates give researchers and policymakers important 
and relevant insight into the future trend of dementia burden.
Dementia has been significantly underrecognized and underestimated in SEAR. This review estimated 
the prevalence of dementia in SEAR and showed that the number of people living with dementia in this 
region is substantial and is expected to rise, with over 10 million people projected to have dementia in 
this region by 2030. In 2015, the total costs of dementia in Southeast Asia reached US$7.3 billion, which 
was around one third of Nepal’s national GDP [1,31]. With the projected increase in dementia preva-
lence, the costs incurred will place a significant financial toll on governments, families and individuals.
There is an urgent need for more epidemiological research on dementia burden in SEAR. Nine out of elev-
en countries in SEAR have no published information on the prevalence of dementia. For future epidemi-
ological studies, there should be greater emphasis on reporting of research findings. Apart from the crude 
dementia prevalence, all studies should aim to report on age-specific and sex-and-age-specific dementia 
prevalence. If resources allow, researchers should also attempt to estimate the prevalence of dementia sub-
types. This information will be very useful for more accurate burden estimation and healthcare planning.
CONCLUSION
This review calls for greater recognition of dementia as a health priority and urges countries in SEAR to 
reassess their approach to addressing dementia. We found a significant burden of dementia in SEAR that 
is projected to nearly double by 2030. Governments should focus on promoting awareness of the condi-
Burden of dementia in the WHO Southeast Asia Region
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tion and giving recognition to the fact that dementia is not just a by-product of aging, but a recognized 
illness that has broad effects on the healthcare system and economy.
We demonstrated that the Bayesian approach offers benefits beyond the traditional frequentist approach 
to estimate disease prevalence and burden, particularly with significantly limited data. We were also able 
to demonstrate that the bayesmeta package running an NNHM model can offer similar estimates to the 
Bayesian JAGS algorithm. Further research is needed to assess if there is an optimal approach for disease 
burden estimates. The Bayesian approach offers a promising methodology for improved estimates and 
should continue to be explored, especially since accessible open source software for this method is now 
available.
Future research should focus on targeting risk factors for dementia in SEAR as well as possible prevention 
measures. These future directions will help address the needs of and bring tailored interventions to vari-
ous types of communities affected by dementia in these countries, with the long-term goal of generating 
greater understanding and policies to decrease the prevalence of this disabling disorder.
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